Oligonucleotide (siRNA) · Gene silencing: PRKAG2 · developed by Atrium Therapeutics
ATR 1072 is an investigational siRNA therapy delivered by intravenous infusion that reduces expression of the PRKAG2 gene. It is being studied in cardiac glycogenosis, hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07738107 | Phase 1/2 | Cardiac Glycogenosis | Recruiting | RNA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cardiac GlycogenosisCardiomyopathyHypertrophicWolff-Parkinson-White Syndrome
Updated Nov 1, 2026. Something wrong or missing? Report it on the RNA page.
See RNA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RNA catalysts and pipeline →